Concepedia

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer

Jon Zugazagoitia, Yuting Liu, Maria Toki, John J. McGuire, Fahad Shabbir Ahmed, Brian S. Henick, Richa Gupta, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper,

Journal of Thoracic Oncology · 2019 · 80 citations · 27 references

DOIFull text

Open access

Concepts

References

27

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

, , +15

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

, , +14

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17